john f manzello president ceo jmanzello@promosome com l.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
John F. Manzello President & CEO jmanzello@promosome PowerPoint Presentation
Download Presentation
John F. Manzello President & CEO jmanzello@promosome

Loading in 2 Seconds...

play fullscreen
1 / 13

John F. Manzello President & CEO jmanzello@promosome - PowerPoint PPT Presentation


  • 367 Views
  • Uploaded on

Promosome LLC, Introduction. John F. Manzello President & CEO jmanzello@promosome.com. Management Team.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'John F. Manzello President & CEO jmanzello@promosome' - RexAlvis


Download Now An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
john f manzello president ceo jmanzello@promosome com

Promosome LLC,

Introduction

John F. ManzelloPresident & CEO

jmanzello@promosome.com

slide2

Management Team

John F. Manzello, President and CEO - Established & outstanding track record of 15 years in Director and Executive level management in business/commercial development, fully focused on the introduction of innovative science for bio-production within the biopharmaceutical industry.

William J. Gedale, Chairman - Managing General Partner of NGN Capital. 35+ years of Operating Management & Investment experience. Funded a number of activities of The Scripps Research Institute.

slide3

Scientific Leadership

Gerald M. Edelman, M.D., Ph.D.,is Chair of Neurobiology at The Scripps Research Institute (TSRI) and, separately, Founder and Director of The Neuroscience Institute. Significant contributions in biophysics, protein chemistry, immunology, cell biology,

and neurobiology. Studies on the structure and diversity of antibodies led to the

Nobel Prize for Physiology or Medicine in 1972.

Vincent P. Mauro, Ph.D., is Associate Professor in the Department of Neurobiology at TSRI. Dr. Mauro and his colleagues have developed selection methodologies to identify IRES elements in mammalian cells and in yeast. He has also demonstrated that powerful synthetic Translational Enhancer Elements (TEEs) can be generated by linking individual IRES elements.

slide4

Scripps – Our Equity Partner

  • Scripps Partnership:
  • 3 Year Laboratory Funding Agreement in place establishing a relationship with Promosome and the laboratories of Drs. Edelman and Mauro;
  • Promosome has exclusive, sole worldwide rights to license discoveries from the laboratory.
  • Scripps 20+% founder’s interest, subject to normal dilution – no future royalties.
slide5

Proprietary Technology Advantage

  • Two Key Components:
  • Selection Technology
  • Translational Enhancer Elements (“TEE”s), including IRESes
  • Substantial Enhancements For:
  • Protein production (90% of Promosomes Current Effort)
  • DNA vaccines (10% of Promosomes Current Effort)
  • Future Opportunities:
  • Special reagents
  • Therapeutics
  • Molecular diagnostics
slide6

Technology Basics

  • Our approach to enhancing protein synthesis involves maximizing translation initiation.
  • Synthetic Translation Enhancement Elements (TEEs)
    • Multiple elements increase number of binding sites
    • More ribosomes are “captured”
    • More protein is created (5-10 Fold Increase of pg/c/d)
  • Development Results Promise Industry Leadership
    • Protein boost of up to 25 fold have been achieved with certain proteins
    • Most recent data has demonstrated 4-5 fold increase (100ml scale) in industry relevant CHO-S lines
    • Works in a variety of mammalian cell lines
    • Works in non-mammalian yeast cell lines
slide7

The Biotech Industry Challenge

Constant Need to Optimize Protein Manufacturing Capacity

Repeated Demand for Next Generation of Bioproduction

Enabling Technologies

Translational Enhancement

1

Promoter

Transcription

Technologies

Cell Line Improvements

100’s

10

Cell Culture Process Development

1000’s

100’s

slide8

The Biotech Industry Challenge

Constant Need to Optimize Protein Manufacturing Capacity

Repeated Demand for Next Generation of Bioproduction

Enabling Technologies

Translational Enhancement

Promoter

Transcription

Technologies

YIELD

Cell Line Improvements

Cell Culture / Process Development

TIME

slide9

The Biotech Industry Challenge

Constant Need to Optimize Protein Manufacturing Capacity

Repeated Demand for Next Generation of Bioproduction

Enabling Technologies

Translational Enhancement

Promoter

Transcription

Technologies

YIELD

Cell Line Improvements

Cell Culture / Process Development

TIME

slide10

The Biotech Industry Relief

  • Lower Capital Cost

(New SS)

  • Improved Return

(Existing SS)

  • Decreased Cost of Goods
  • Increased Margins
  • Greater Speed to Market
  • Competitive Advantage g/l
  • Enablement of Shelved
  • “Hard to Make” Proteins
slide11

Market Advantage

  • Our translational approach has been presented to leading Bio-Process Service firms and major Biotech players. The general consensus has been:

The Most Advanced Molecular Solutions Currently Available

Excellent Market Timing

Fully Complementary to Previous Industry Advances

Purveyors and End Users of Transcriptional Approaches are All Potential Collaborators or Customers

Solid IP and Freedom to Practice

slide12

Investment

Promosome expects to achieve revenues of $16 M by Year 3

Pretax margins anticipated at 35%

Raised $1.9 Million in 2003

Institutional investors (17.8%)

Private entities (19.8%)

Management & board (18.9%)

Scientific team (21.2%)

Scripps (21.2%) plus consultants (1% as warrants)

$7 M in Series B Preferred equity

All Series A shareholders plus three new investors have combined to invest $2M Series B “Bridge” in April of 2007. The balance of the B round is anticipated to close Q1 2008.

slide13

Summary

Unique model

Drives early revenue while positioning company for higher-value therapeutic development

World-Class Scientific Team

Partnership & Continuing Support from Scripps

Exceptional Market Timing

Solid Industry Management

Grants & Prior Funding, Lower Investment Risk

Early Adopters Being Positioned